Status:
UNKNOWN
Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
Lead Sponsor:
Qilu Hospital of Shandong University
Conditions:
HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
Eligibility:
MALE
50-90 years
Brief Summary
This study is a single center, non-interference, retrospective registration study: HER2 testing and disease information collection were conducted on patients diagnosed with prostate cancer and able to...
Detailed Description
1. To explore the expression of HER2 protein in prostate cancer patients admitted to Qilu Hospital of Shandong University, especially the expression rate of HER2 protein under different pathological c...
Eligibility Criteria
Inclusion
- 1\. Prostate cancer patients confirmed by histopathology in our hospital from January 2018 to July 2023;
- 2\. Men aged ≥ 18 years old;
- 3\. The expected survival time is greater than 12 weeks;
- 4\. The KPS functional status score is greater than 60, and the ECOG status score is 0-2 points;
- 5\. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.
Exclusion
- \- 1. Those who have been diagnosed with tumors in other parts, such as lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer, etc. (except for cancer in situ or non melanoma skin cancer, or combined tumors with low recurrence probability within a few years);
- 2\. According to the researcher's judgment, there are other patients who are not suitable for inclusion.
Key Trial Info
Start Date :
July 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06146114
Start Date
July 1 2023
End Date
December 1 2024
Last Update
November 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu hospital
Jinan, Shandong, China, 276600